AngioTarget BV is a spin-off company of the VU University Medical Center (VUMC) in Amsterdam, The Netherlands. Through
a strategic collaboration between VUMC, the Angiogenesis Laboratory and AngioTarget, proprietary targets
discovered in the Angiogenesis Laboratory are exploited for the development of diagnostic imaging strategies for cancer.
of ongoing angiogenesis has great potential for assessment of therapy
response, but can also be used for prediction of therapy response.
Biomarkers for therapy response are not available yet, but are
seriously needed to prevent prescription of expensive and ineffective
therapy and to gain time in the course of therapy, from the patient's
is also dedicated to the developement of therapeutic strategies based
on targeting proprietary markers of the tumor vasculature. A novel
strategy for vaccination against the tumor vasculature has been
developed, making use of antibody inducing conjugate vaccines.
AngioTarget BV. has its own research premises at the incubator facility of the VU University.